$179 Million

GW Pharmaceuticals

Follow-on Offering

Bookrunner, April 2015

GW Pharmaceuticals
GW Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead cannabinoid product is Epidiolex, a pharmaceutical oral formulation of cannabidiol, or CBD, for which the Company retains global commercial rights. Epidiolex was approved by the U.S. Food and Drug Administration, or FDA, on June 25, 2018, for the treatment of seizures associated with lennox-gastaut syndrome, or LGS, or dravet syndrome, or Dravet syndrome, in patients two years of age and older. LGS and Dravet syndrome are severe childhood-onset, drug-resistant epilepsy syndromes. GWPH, along with its U.S. subsidiary Greenwich Biosciences, announced that Epidiolex is being rescheduled by the DEA. The Company expects to commercially launch in Fall 2018 post-announcement.